Int. Journal of Clinical Pharmacology and Therapeutics, Volume 60 (2022) - November (469 - 476)

Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan
Kazuhiro Kawabe1, 2, Toshimitsu Nakayama3, Noriyasu Fukuoka1, Yasutaka Sakamoto2, Hirohito Goto2, Taiichi Suzuki2, Hirofumi Koike2, Yukiko Sahashi2, Nobuhiro Ooba1
1 Nihon University School of Pharmacy, Funabashi, Chiba, 2 Department of Pharmacy, Yokohama City University Hospital, Yokohama, Kanagawa, and 3 Nihon University Itabashi Hospital Clinical Research Center, Tokyo, Japan

Add to Cart  

 

DOI 10.5414/CP204259

Abstract

Objective: The effectiveness of imatinib, a tyrosine kinase inhibitor recommended for the treatment of chronic myeloid leukemia, is associated with high adherence and trough plasma imatinib concentrations of ~ 1,000 ng/mL. However, adherence and therapeutic drug monitoring (TDM) for imatinib have hardly been reported. This study evaluated the prevalence of TDM and adherence to imatinib for chronic myeloid leukemia in Japan.
Materials and methods: Monthly insurance claims data for ~ 5.6 million individuals aged 20 – 74 years between June 1, 2005 and December 31, 2017 were studied. Patients with at least one prescription for imatinib were included to calculate adherence and the annual mean prevalence of TDM for imatinib.
Results: A total of 498 patients with 9,620 prescriptions of imatinib were included. After 2013, the number of imatinib prescriptions and the number of patients treated with imatinib were over 1,000 and 200, respectively. The mean annual prevalence of TDM for imatinib was 12.2% (95% confidence interval (CI), 8.1 – 16.1%). Antihyperuricemic drugs and steroids increased the likelihood of TDM. The medication possession ratio for assessment of adherence was 93.5% (95% CI: 91.8 – 95.5%). The annual mean prevalence of TDM for imatinib was low, although adherence was high.
Conclusion: To encourage the measurement of plasma concentrations of imatinib in clinical settings, adding a package insert, a summary of product characteristics, and a patient information leaflet regarding the implementation of TDM is justified and warrants further attention.

Author Details

Authors

Departments

  • 1 Nihon University School of Pharmacy, Funabashi, Chiba,
  • 2 Department of Pharmacy, Yokohama City University Hospital, Yokohama, Kanagawa, and
  • 3 Nihon University Itabashi Hospital Clinical Research Center, Tokyo, Japan

Address

Prof. Nobuhiro Ooba
Nihon University School of Pharmacy
7-7-1 Narashinodai, Funabashi
Chiba 274-8555, Japan
Email: [email protected]

Log in for Subscribers

Citation

Kazuhiro Kawabe, Toshimitsu Nakayama, Noriyasu Fukuoka, Yasutaka Sakamoto, Hirohito Goto, Taiichi Suzuki, Hirofumi Koike, Yukiko Sahashi, Nobuhiro Ooba. Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan. Int J Clin Pharmacol Ther. 2022; 60: 469-476. doi: 10.5414/CP204259. Pubmed: https://pubmed.ncbi.nlm.nih.gov/35924643/; PMID: 35924643.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart